Caracterización epidemiológica y clínica de la cirrosis hepática en un centro regional del caribe colombiano: clínica general del norte. Enero 2012 a marzo 2017.

Caracterizar epidemiológicamente y clínicamente a los pacientes con diagnóstico de cirrosis hepática en región Caribe Colombiana, que reciben atención en la Unidad de Gastroenterología y Hepatología de la Clínica General del Norte, durante el periodo enero de 2012 a marzo de 2017. Materiales y Mé...

Descripción completa

Detalles Bibliográficos
Autores Principales: Escorcia Charris, Edgardo José, Marrugo Balceiro, Wilson Rafael
Formato: Trabajo de grado (Bachelor Thesis)
Lenguaje:Español (Spanish)
Publicado: 2017
Materias:
Acceso en línea:https://hdl.handle.net/10901/10705
id ir-10901-10705
recordtype dspace
spelling Ortega, Rolando
Iglesias Acosta, Jesús E.
Escorcia Charris, Edgardo José
Marrugo Balceiro, Wilson Rafael
Barranquilla
2017-10-25T20:23:07Z
2017-10-25T20:23:07Z
2017
https://hdl.handle.net/10901/10705
instname:Universidad Libre
reponame:Repositorio Institucional Universidad Libre
Caracterizar epidemiológicamente y clínicamente a los pacientes con diagnóstico de cirrosis hepática en región Caribe Colombiana, que reciben atención en la Unidad de Gastroenterología y Hepatología de la Clínica General del Norte, durante el periodo enero de 2012 a marzo de 2017. Materiales y Métodos: Estudio descriptivo transversal y retrospectivo; muestra por conveniencia de 284 pacientes con diagnóstico de cirrosis hepática, ya sea clínico, de laboratorio, imagenológico o histopatológico. La tabulación de la información se realizó en programa Epi-Info 7.0; se valoraron parámetros estadísticos descriptivos. Resultados: El 70.4% de los pacientes procedían del departamento del Atlántico, el principal motivo de consulta fue la imagen hepática alterada en estudios de imagen 36,2%; la etiología de mayor frecuencia fue por virus C con el 28,5%, el 66.2% presentó enfermedad bien compensada (CHILD-A). Conclusiones: La etiología por virus de hepatitis C es la de mayor prevalencia en el medio local, le siguen en frecuencia el hígado graso no alcohólico, la hepatitis autoinmune, la cirrosis biliar primaria, el alcohol, viral hepatitis B y otras etiologías.
To characterize epidemiologically and clinically patients diagnosed with liver cirrhosis in the Colombian Caribbean region, receiving care in the Gastroenterology and Hepatology Unit of the Clínica General del Norte, from January 2012 to March 2017. Materials and methods: Descriptive cross-sectional and retrospective study; sample for the convenience of 284 patients with diagnosis of hepatic cirrhosis, whether clinical, laboratory, imaging or histopathological. The information was tabulated in Epi-Info 7.0 program, descriptive statistical parameters were evaluated. Results: 70.4% of the patients came from the Atlantico department, main reason for consultation was altered liver imaging in imaging studies 36.2%; the most frequent etiology was C virus with 28.5%, 66.2% had well-compensated disease (CHILD-A). Conclusions: The etiology of hepatitis C virus is the most prevalent in the local environment, followed by non-alcoholic fatty liver, autoimmune hepatitis, primary biliary cirrhosis, alcohol, viral hepatitis B and other etiologies.
PDF
application/pdf
spa
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Atribución-NoComercial-SinDerivadas 2.5 Colombia
info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
Cirrosis hepática
Epidemiologia
Medicina
Liver cirrhosis.
Epidemiology
Epidemiología
Cirrosis Hepática
Cirrosis Hepática
Epidemiología
Caracterización epidemiológica y clínica de la cirrosis hepática en un centro regional del caribe colombiano: clínica general del norte. Enero 2012 a marzo 2017.
Tesis de Especialización
info:eu-repo/semantics/acceptedVersion
http://purl.org/coar/resource_type/c_7a1f
http://purl.org/coar/version/c_ab4af688f83e57aa
info:eu-repo/semantics/bachelorThesis
Samada M, Hernández J, Barroso L, Chao L, González M, Fernández I. Identificación de factores de riesgo de presencia de várices esofágicas en pacientes con cirrosis hepática. Rev Cub Med Mil. 2008;37(1):1-8
Alonso F, Garmendia M, De Aguirre M, Searte J. Análisis de la Tendencia de la Mortalidad por Cirrosis hepática en Chile. Re Med Chile 2010; 138:1253-8
Lebroc D, Reina A, Camacho J, Massip M. Caracterización Clínica de los Pacientes con Cirrosis Hepática en el Hospital Provincial Docente “Doctor Antonio Luaces Iraola”. MediCiego 2011, 17(2)
Torre A. Complicaciones de la cirrosis hepática: ascitis, encefalopatía, síndrome hepatorrenal y estado nutricional. Revista de Gastroenterología de México. 2014;79(1):5-7
Campollo O, Valencia J, Berumen A, Perez M, Pandero A, Segura J. Características epidemiológicas de la cirrosis hepática en el Hospital Civil de Guadalajara. Salud pública de México.1997;39(3):195-200
Bustios C, Davalos M, Roman R, Zumaeta E. Características Epidemiológicas y Clínicas de la Cirrosis Hepática en la Unidad de Hígado del HNERM Es-Salud. Rev. gastroenterol. 2007;27(3):238-245.
Giraldo A, Barraza M, Villa H, Martínez J, García G. Caracterización epidemiológica de pacientes con cirrosis en una consulta de gastroenterología en Pereira, Colombia, 2009-2012. Rev. Méd. Risaralda 2014; 20 (2):86-94
Prieto J, Sánchez S, Prieto R, Rojas E, González L, Mendivelso F. Características clínicas y descompensación en pacientes con cirrosis hepática atendidos en dos centros de hepatología en la ciudad de Bogotá D.C., 2010-2014. Rev Col Gastroenterol 2016;31(1):1-8
Martirani, A; Wajchenberg, B; Souza, R; Carvalho, A; et al. Toxic (postnecrotis) cirrosis of the liver in childhood. Gastroenterology. 1957;32:304
More E. Características clínicas y epidemiológicas de la cirrosis hepática en un hospital de la ciudad de Lima. Tesis de gradop en Gastroenterologia. Fac Med Hum. 2015; 1-92
Mandrekar P, Szabo G: Inflammation and liver injury. In Monga SPS, editor: Molecular pathology of liver diseases, New York, 2011, Springer, pp 411–425.
Lefton HB, Rosa A, Cohen M. Diagnosis and epidemiology of cirrhosis. Med Clin North Am. 2009;93:787-99
Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749-61.
Leandro G, Mangia A, Hui J. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C; a meta-analysis of individual patient data. Gastroenterology 2006; 130:1636–42.
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592.
Bajaj JS, Ahluwalia VS, Sikaroodi M, et al. Altered gut microbiome is associated with neuroinflammation on brain MRI in cirrhosis: Implications for the gut-liver-brain axis. Sesión de carteles presentada en: EASL 2014 abril 9-13; Londres, Reino Unido. p 499
Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis 2008;3:1–17.
Cortes-Mancera F, Loureiro CL, Hoyos S, Restrepo JC, Correa G, Jaramillo S, Norder H, Pujol FH, Navas MC. Etiology and Viral Genotype in Patients with End-Stage Liver Diseases admitted to a Hepatology Unit in Colombia. Hepatitis Research and Treatment. 2011;2011:363205.
Hartroft WS. The trabecular anatomy of late stages of experimental dietary cirrhosis. Anat. Rec. 1954; 119: 71–94
Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. J. Clin. Pathol. 1978; 31: 395–414.
Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin. Liver Dis. 2001; 21: 351–72
Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J. Cell Mol. Med. 2006; 10: 76–99.
Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin. Chim. Acta 2006; 364: 33–60
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128.
García, G. La cirrosis y sus secuelas. Goldman-Cecil. Tratado de medicina interna. 25ª Edición. Elsevier; 2017.
García-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology. 2010;51:1445-9.
Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593–608.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45(2):507–39.
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838–51
Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51:1445–49
Charlton M. Non-alcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048–58.
Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis 2008;3:1–17.
Lindor KD. Characteristics of primary sclerosing cholangitis in the USA. Hepatol Res 2007;37(3):S474–7.
Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol 2008;24(3):298–305.
Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47(6):2089–111.
Adams PC, Barton JC. Hemochromatosis. Lancet 2007;370(9602):1855–60
Mandrekar P, Szabo G: Inflammation and liver injury. In Monga SPS, editor: Molecular pathology of liver diseases, New York, 2011, Springer, pp 411–425.
Lee UE, Friedman SL: Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 25(2):195–206, 2011
Iwaisako K, Brenner DA, Kisseleva T: What’s new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol 27(Suppl 2):65–68, 2012
McGuire RF, Bissell DM, Boyles J, Roll FJ. Role of extracelular matrix in regulating fenestrations of sinusoidal endotelial cells isolated from normal rat liver. Hepatology 1992
Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005; 10: 927-939
March S, Hui EE, Underhill GH, Khetani S, Bhatia SN. Mi croenvironmental regulation of the sinusoidal endothelial cell phenotype in vitro. Hepatology 2009; 50: 920-928
Lakner AM, Steuerwald NM, Walling TL, Ghosh S, Li T, McKillop IH, Russo MW, Bonkovsky HL, Schrum LW. Inhibitory effects of microRNA 19b in hepatic stellate cellmediated fibrogenesis. Hepatology 2012; 56: 300-310
Tacke F, Weiskirchen R: Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques. Expert Rev Gastroenterol Hepatol 6(1):67–80, 2012
Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol 2006; 12: 7413-7420
Pellicoro A, et al: Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 14(3):181–194, 2014.
Pradere JP, et al: Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 58(4):1461–1473, 2013.
Tacke F, Zimmermann HW: Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 60(5):1090–1096, 2014.
Deaciuc IV, Spitzer JJ. Hepatic sinusoidal endothelial cell in alcoholemia and endotoxemia. Alcohol Clin Exp Res 1996; 20: 607-614
ål P, Broomé U, Scheynius A, Befrits R, Hultcrantz R. Kupffer cell iron overload induces intercellular adhesión molecule-1 expression on hepatocytes in genetic hemochromatosis. Hepatology 1995; 21: 1308-1316
Mehal W, Imaeda A. Cell death and fibrogenesis. Semin Liver Dis 2010; 30: 226-231
Guicciardi ME, Gores GJ. Apoptosis as a mechanism for liver disease progression. Semin Liver Dis 2010; 30: 402-410
Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708-1717
Marshall A, Rushbrook S, Davies SE, Morris LS, Scott IS, Vowler SL, Coleman N, Alexander G. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. Gastroenterology 2005; 128: 33-42
Syn WK, et al: Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 51(6):1998–2007, 2010
Marra F, et al: Mononuclear cells in liver fibrosis. Semin Immunopathol 31(3):345–358, 2009.
Muhanna N, et al: Lymphocyte-hepatic stellate cell proximity suggests a direct interaction. Clin Exp Immunol 148(2):338–347, 2007.
Hartmann P, Haimerl M, Mazagova M, Brenner DA, Schnabl B. Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology. 2012; 143:1330–1340. e1331.
Hammerich L, Heymann F, Tacke F. Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol. 2011; 2011:345803.
Feng D, Wang Y, Wang H, Weng H, Kong X, Martin-Murphy BV, et al. Acute and chronic effects of IL-22 on acetaminophen-induced liver injury. J Immunol. 2014; 193:2512–2518.
Dooley S, ten Dijke P. TGF-beta in progression of liver disease. Cell Tissue Res. 2012; 347:245–256.
Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604–20.
García-Pagán JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 2012; 57: 458–61.
Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246–56.e5.
Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245–51.
Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology. 2008; 135:1729–1738.
D’Amico G, García-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-31.
Nagula S, Jain D, Groszmann RJ, García-Tsao G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol. 2006;44:111-7.
Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fi brosis and liver stiff ness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970–79, e1–3.
Dufour D, Lott J, Nolte F, et al. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000;46:2050–68.
Lu LG, Zeng MD, Mao YM, et al. Relationship between clinical and pathologic findings in patients with chronic liver diseases. World J Gastroenterol 2003; 9(12):2796–800
Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007;46(1):32–6.
Rossi E, Adams L, Prins A, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49(3): 450
Gupta A, Kim D, Krinsky G, et al. CT and MRI of cirrhosis and its mimics. AJR Am J Roentgenol 2004;183:1595–601.
Ginès P, Cabrera J, Guevara M, Morillas R, Ruiz del Árbol L, Solà R y Soriano G. Modelos pronósticos en la cirrosis hepática. El modelo MELD Documento de consenso sobre el tratamiento de la ascitis, la hiponatremia dilucional y el síndrome hepatorrenal en la cirrosis hepática. Gastroenterol Hepatol 2004; 27(9):535-44
Groszmann RJ, Garcia-Tsao G, Bosch J, et al: Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: pp. 2254-2261
Ripoll C, Groszmann R, Garcia-Tsao G, et al: Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133: pp. 481-488
Gluud LL, Klingenberg S, Nikolova D, and Gluud C: Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol 2007; 102: pp. 2842-2848
Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J, and Bosch J: Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: pp. 902-908
Garcia-Tsao G, and Bosch J: Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362: pp. 823-832
Bañares R, Albillos A, Rincón D, et al: Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a metaanalysis. Hepatology 2002; 35: pp. 609-615
Goulis J, Patch D, and Burroughs AK: Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999; 353: pp. 139-142
D'Amico G, Garcia-Tsao G, and Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: pp. 217-231
Fede G, D'Amico G, Arvaniti V, et al: Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012; 56: pp. 810-818
Runyon BA: Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: pp. 2087-2107
Angeli P, Fasolato S, Mazza E, et al: Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut 2010; 59: pp. 98-104
Ginès P, Titó L, Arroyo V, et al: Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: pp. 1493-1502
Bureau C, Métivier S, D'Amico M, et al: Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol 2011; 54: pp. 901-907
Arvaniti V, D'Amico G, Fede G, et al: Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: pp. 1246
Fernández J, Navasa M, Planas R, et al: Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: pp. 818-824
Sort P, Navasa M, Arroyo V, et al: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: pp. 403-409
Jepsen P, Ott P, Andersen PK, Sørensen HT, and Vilstrup H: Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51: pp. 1675-1682
Jepsen P, Ott P, Andersen PK, Sørensen HT, and Vilstrup H: Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51: pp. 1675-1682
Bai M, Yang Z, Qi X, Fan D, and Han G: l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2013; 28: pp. 783-792
Bass NM, Mullen KD, Sanyal A, et al: Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: pp. 1071-1081
institution Universidad Libre de Colombia
collection DSpace
title Caracterización epidemiológica y clínica de la cirrosis hepática en un centro regional del caribe colombiano: clínica general del norte. Enero 2012 a marzo 2017.
spellingShingle Caracterización epidemiológica y clínica de la cirrosis hepática en un centro regional del caribe colombiano: clínica general del norte. Enero 2012 a marzo 2017.
Escorcia Charris, Edgardo José
Marrugo Balceiro, Wilson Rafael
Cirrosis hepática
Epidemiologia
Medicina
Liver cirrhosis.
Epidemiology
Epidemiología
Cirrosis Hepática
Cirrosis Hepática
Epidemiología
title_short Caracterización epidemiológica y clínica de la cirrosis hepática en un centro regional del caribe colombiano: clínica general del norte. Enero 2012 a marzo 2017.
title_full Caracterización epidemiológica y clínica de la cirrosis hepática en un centro regional del caribe colombiano: clínica general del norte. Enero 2012 a marzo 2017.
title_fullStr Caracterización epidemiológica y clínica de la cirrosis hepática en un centro regional del caribe colombiano: clínica general del norte. Enero 2012 a marzo 2017.
title_full_unstemmed Caracterización epidemiológica y clínica de la cirrosis hepática en un centro regional del caribe colombiano: clínica general del norte. Enero 2012 a marzo 2017.
title_sort caracterización epidemiológica y clínica de la cirrosis hepática en un centro regional del caribe colombiano: clínica general del norte. enero 2012 a marzo 2017.
author Escorcia Charris, Edgardo José
Marrugo Balceiro, Wilson Rafael
author_facet Escorcia Charris, Edgardo José
Marrugo Balceiro, Wilson Rafael
topic Cirrosis hepática
Epidemiologia
Medicina
Liver cirrhosis.
Epidemiology
Epidemiología
Cirrosis Hepática
Cirrosis Hepática
Epidemiología
topic_facet Cirrosis hepática
Epidemiologia
Medicina
Liver cirrhosis.
Epidemiology
Epidemiología
Cirrosis Hepática
Cirrosis Hepática
Epidemiología
publishDate 2017
language Español (Spanish)
format Trabajo de grado (Bachelor Thesis)
description Caracterizar epidemiológicamente y clínicamente a los pacientes con diagnóstico de cirrosis hepática en región Caribe Colombiana, que reciben atención en la Unidad de Gastroenterología y Hepatología de la Clínica General del Norte, durante el periodo enero de 2012 a marzo de 2017. Materiales y Métodos: Estudio descriptivo transversal y retrospectivo; muestra por conveniencia de 284 pacientes con diagnóstico de cirrosis hepática, ya sea clínico, de laboratorio, imagenológico o histopatológico. La tabulación de la información se realizó en programa Epi-Info 7.0; se valoraron parámetros estadísticos descriptivos. Resultados: El 70.4% de los pacientes procedían del departamento del Atlántico, el principal motivo de consulta fue la imagen hepática alterada en estudios de imagen 36,2%; la etiología de mayor frecuencia fue por virus C con el 28,5%, el 66.2% presentó enfermedad bien compensada (CHILD-A). Conclusiones: La etiología por virus de hepatitis C es la de mayor prevalencia en el medio local, le siguen en frecuencia el hígado graso no alcohólico, la hepatitis autoinmune, la cirrosis biliar primaria, el alcohol, viral hepatitis B y otras etiologías. To characterize epidemiologically and clinically patients diagnosed with liver cirrhosis in the Colombian Caribbean region, receiving care in the Gastroenterology and Hepatology Unit of the Clínica General del Norte, from January 2012 to March 2017. Materials and methods: Descriptive cross-sectional and retrospective study; sample for the convenience of 284 patients with diagnosis of hepatic cirrhosis, whether clinical, laboratory, imaging or histopathological. The information was tabulated in Epi-Info 7.0 program, descriptive statistical parameters were evaluated. Results: 70.4% of the patients came from the Atlantico department, main reason for consultation was altered liver imaging in imaging studies 36.2%; the most frequent etiology was C virus with 28.5%, 66.2% had well-compensated disease (CHILD-A). Conclusions: The etiology of hepatitis C virus is the most prevalent in the local environment, followed by non-alcoholic fatty liver, autoimmune hepatitis, primary biliary cirrhosis, alcohol, viral hepatitis B and other etiologies.
geographic_facet Barranquilla
url https://hdl.handle.net/10901/10705
_version_ 1779705301295955968
score 12,131701